Incyte | INCY - Current Liabilities


Incyte reported $1.49B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Agenus USD 249.24M 74.25M Mar/2026
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amgen USD 24.96B 534M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Biogen USD 3B 350.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Exelixis USD 370.98M 34.67M Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
MacroGenics USD 95.94M 52.82M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Moderna USD 2.4B 408M Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Novartis USD 27.28B 4.72B Dec/2025
Pfizer USD 34.35B 2.64B Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026